Improving survival in metastatic renal cell carcinoma (mRCC) patients: do elderly patients benefit from expanded targeted therapeutic options?

Hendrik EggersChristoph SchünemannViktor GrünwaldLinda RudolphMaria-Luisa TiemannChristoph ReuterMerle Freya Anders-MeynArnold GanserPhilipp Ivanyi

Published in: World journal of urology (2022)

Improved OS in the targeted treatment period was confirmed. Surprisingly elderly and old patients seem to profit the most form expansion of therapeutic armamentarium, within the TKI-dominated observation period.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes
drug delivery
advanced non small cell lung cancer
patient reported
community dwelling
chronic myeloid leukemia